Souhaitez-vous accéder aux communiqués récents ?

Predictive receives first tranche of financing to initiate integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States ...

PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today closed its...

PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today announced...

Company successfully identified several abandoned or discontinued drugs for further testing and development in ovarian and other cancer types Creates significant business development opportunities...

Study used Predictive Oncology’s vast biobank of cryopreserved live cell tumor specimens for the production and testing of primary patient tumor spheroids Results presented at the 2025 Society for...

Initial plans target European clinical trials while providing standard testing to clinicians for individual patients There are an estimated 250,000 gynecologic cancers diagnosed annually across...

- Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications – - Deal terms align shareholders’...

PITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced progress in its ongoing evaluation of strategic...

PITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities,...

PITTSBURGH, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, is scheduled to deliver a virtual presentation and host...